BNP Paribas Financial Markets’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-140
| Closed | -$210 | – | 4059 |
|
|
2023
Q1 | $210 | Sell |
140
-545
| -80% | -$734 | ﹤0.01% | 3760 |
|
|
2022
Q4 | $684 | Buy |
685
+545
| +389% | +$735 | ﹤0.01% | 3842 |
|
|
2022
Q3 | $252 | Sell |
140
-2,761
| -95% | -$8.01K | ﹤0.01% | 4590 |
|
|
2022
Q2 | $8.41K | Sell |
2,901
-91,594
| -97% | -$226K | ﹤0.01% | 3765 |
|
|
2022
Q1 | $261K | Sell |
94,495
-37,400
| -28% | -$118K | ﹤0.01% | 3036 |
|
|
2021
Q4 | $615K | Buy |
131,895
+124,064
| +1,584% | +$776K | ﹤0.01% | 2904 |
|
|
2021
Q3 | $66.6K | Buy |
7,831
+4,375
| +127% | +$61.8K | ﹤0.01% | 3433 |
|
|
2021
Q2 | $56.7K | Sell |
3,456
-19,808
| -85% | -$400K | ﹤0.01% | 3223 |
|
|
2021
Q1 | $514K | Buy |
23,264
+19,672
| +548% | +$536K | ﹤0.01% | 2552 |
|
|
2020
Q4 | $111K | Sell |
3,592
-2,419
| -40% | -$61.2K | ﹤0.01% | 3157 |
|
|
2020
Q3 | $122K | Buy |
6,011
+5,359
| +822% | +$94.1K | ﹤0.01% | 3004 |
|
|
2020
Q2 | $10K | Sell |
652
-2,965
| -82% | -$34.2K | ﹤0.01% | 3707 |
|
|
2020
Q1 | $28K | Buy |
3,617
+904
| +33% | +$11.1K | ﹤0.01% | 3808 |
|
|
2019
Q4 | $38.7K | Buy |
2,713
+1,370
| +102% | +$21.2K | ﹤0.01% | 3779 |
|
|
2019
Q3 | $20.2K | Buy |
1,343
+1,265
| +1,622% | +$19.7K | ﹤0.01% | 3945 |
|
|
2019
Q2 | $1.12K | Buy |
+78
| New | +$1.24K | ﹤0.01% | 4363 |
|
BNP Paribas Financial Markets's TCRR Position: Q2 2023 in Review
BNP Paribas Financial Markets sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 140 shares — an estimated $210 sold.
BNP Paribas Financial Markets first reported a position in TCRR in Q2 2019 and held it in 16 quarters. The position peaked at $615K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- BNP Paribas Financial Markets reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BNP Paribas Financial Markets sold 140 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $210.
- BNP Paribas Financial Markets first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- BNP Paribas Financial Markets's TCR2 Therapeutics Inc. Common Stock position peaked at $615K in Q4 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2023, filed 9 Aug 2023.